In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased significantly in value. Abbott received CE Mark approval for FreeStyle® Libre in September 2014 and for FreeStyle® 2 in October 2018. The company also launched FGM in the U.S. market in late 2017 and has expanded to numerous international
Throughout this medical market research, we analyzed over 90 diabetes companies across 16 countries and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. While this MedSuite report contains all the Global Diabetes Monitoring, Treatment and Drug Delivery data and analysis, each of the market segments
In 2018, the fastest-growing segment in the diabetes care market was the FGM market, which increased dramatically in value. The high level of growth was attributed to the commercial launch of FGM in late 2017. Abbott received FDA approval for FreeStyle® Libre in September 2017 and for FreeStyle® Libre 14 Day in July 2018. The
Blood glucose meters are electronic devices that analyze a small drop of blood that is drawn using a lancet and lancing device. The blood is placed on a small disposable test strip that is inserted into the blood glucose meter, which reads the level of glucose in the blood. The blood glucose meter is battery-powered and fits in the palm of the hand. When the blood is placed on the strip, it flows in through capillary action. The electrochemical reaction between the test strip and the blood determines the blood glucose concentration reported as milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L).